# US 2022/0031773 A1 · Methods and Compositions for Treating Ulcerative Colitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031773 A1
- Document ID: US20220031773A1
- Status: Published application
- Kind: A1
- Application number: 17/505,029
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2018-07-13
- Assignees: Finch Therapeutics Holdings LLC
- Applicants: Finch Therapeutics Holdings LLC
- Inventors: Thomas Julius BORODY
- Web page: https://patentgrep.com/patent/US20220031773A1

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 33/56916: {Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.

## Claims

### Claim 1

A pharmaceutical composition comprising viable non-pathogenic bacteria from one or more first microbial taxa selected from the group consisting of Clostridium cluster XVIII, Ruminococcus, Lachnospiraceae, Roseburia inulinivorans, Eubacterium hallii, and any combination thereof, wherein said pharmaceutical composition contains no bacteria from one or more second microbial taxa selected from the group consisting of Fusobacterium, Sutterella, Haemophilus, Escherichia, Megamonas, Clostridium cluster XIVa, Prevotella, Dialister, Veillonella, and Bilophila.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein said second microbial taxon is selected from the group consisting of Fusobacterium gonidiaformans, Prevotella copri, and Sutterella wadsworthensis.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein said viable non-pathogenic bacteria is from a synthetic culture.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is in an anaerobic package or container.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is in a liquid, frozen, freeze-dried, spray-dried, lyophilized, or powder form.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises an excipient, a saline, a buffer, a buffering agent, or a fluid-glucose-cellobiose agar (RGCA) media.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises a cryoprotectant.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein said pharmaceutical composition comprises a cryoprotectant comprising polyethylene glycol, skim milk, erythritol, arabitol, sorbitol, glucose, fructose, alanine, glycine, proline, sucrose, lactose, ribose, trehalose, dimethyl sulfoxide (DMSO), glycerol, or a combination thereof.

### Claim 9

A method for producing a pharmaceutical composition, said method comprising
a) determining in a candidate fecal microbe source material the relative abundance of one or more bacterial markers selected from the group consisting of Bacteroides OTU187, Bacteroides fragilis, Bacteroides finegoldii, Clostridium cluster XlVa (OTU173), Streptococcus (OTU56), Sutterella wadsworthensis, Bacteroides uniformis, and Bacteroides coprocola;
b) selecting said candidate fecal microbe source material if the relative abundance of Bacteroides OTU187, Bacteroides fragilis, or Bacteroides finegoldii is above a pre-determined lowest limit, and/or if the relative abundance of Clostridium cluster XlVa (OTU173), Streptococcus (OTU56), Sutterella wadsworthensis, Bacteroides uniformis, or Bacteroides coprocola is below a pre-determined highest limit; and
c) producing a pharmaceutical composition from said selected fecal microbe source material.

### Claim 10 (depends on 9)

The method of claim 9, wherein said pharmaceutical composition is for treating UC.

### Claim 11 (depends on 9)

The method of claim 9, wherein said fecal microbe source material is derived from one or more human donors.

### Claim 12 (depends on 9)

The method of claim 9, wherein said candidate fecal microbe source material is a substantially complete fecal microbiota from a donor.

### Claim 13

A method for selecting a fecal microbe source material, said method comprising
a) Determining in a candidate fecal microbe source material the relative abundance of one or more markers from a metabolic pathway selected from the group consisting of fatty acid biosynthesis, propanoate metabolism, secondary bile acid biosynthesis, glycerophospholipid metabolism, biosynthesis of ansamycins, terpenoid backbone biosynthesis, bacterial chemotaxis, heme biosynthesis, and short chain fatty acid (SCFA) biosynthesis; and
b) selecting said candidate fecal microbe source material based on the relative abundance of said one or more markers.

### Claim 14 (depends on 13)

The method of claim 13, wherein said fecal microbe source material is selected for producing a pharmaceutical composition for treating UC.

### Claim 15 (depends on 13)

The method of claim 13, wherein said one or more markers are metabolic markers.

### Claim 16 (depends on 13)

The method of claim 13, wherein said one or more markers comprise one or more metabolic pathway genes.

### Claim 17 (depends on 13)

The method of claim 13, wherein said relative abundance of said one or more markers is above a pre-determined lowest limit, and said one or more markers are selected from the group consisting of fatty acid biosynthesis, propanoate metabolism, secondary bile acid biosynthesis, glycerophospholipid metabolism, biosynthesis of ansamycins.

### Claim 18 (depends on 13)

The method of claim 13, wherein said relative abundance of said one or more markers is below a pre-determined highest limit, and said one or more markers are selected from the group consisting of terpenoid backbone biosynthesis, bacterial chemotaxis, and heme biosynthesis.

### Claim 19 (depends on 13)

The method of claim 13, wherein said fecal microbe source material is derived from one or more human donors.

### Claim 20 (depends on 13)

The method of claim 13, wherein said candidate fecal microbe source material is a substantially complete fecal microbiota from a donor.
